Epigenomics' Q3 Revenues Fall 29 Percent; PMA Submission Targeted for Epi proColon 2.0 | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – German cancer molecular diagnostics firm Epigenomics today reported revenues in the third quarter fell 29 percent year over year while its net loss increased by 60 percent.

For the three months ended Sept. 30, revenues totaled €257,000 ($349,000), compared to €363,000 ($493,000) a year ago, while its net loss rose to €4.8 million from €3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.